Thomas D. Salus - 14 Apr 2025 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Reporting relationship: Chief Legal & Administration
Issuer ticker: LFCR
Reported as of: 14 Apr 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Apr 2025, 16:38:47 UTC
Next SEC filing: 10 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Rebecca Hilt, Attorney-In-Fact for Thomas D Salus

Key filing fact

Thomas D. Salus filed Form 4 for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) on 16 Apr 2025.

Key facts

This page summarizes Thomas D. Salus's Form 4 filing for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 16 Apr 2025, 16:38.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LFCR transaction

Common Stock

Award

Transaction value
Shares: +45,000
Change %
Price
Shares after: 45,000
Date: 14 Apr 2025
Ownership: Direct
Footnotes: F1

LFCR transaction

Common Stock

Award

Transaction value
Shares: +170,000
Change %: +378%
Price
Shares after: 215,000
Date: 14 Apr 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LFCR transaction Derivative

Performance-Based Restricted Stock Units

Award

Transaction value: $0
Shares: +370,000
Change %
Price: $0.000000
Shares after: 0
Date: 14 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 370,000
Exercise price
Footnotes: F2, F3, F4

LFCR transaction Derivative

Incentive Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +210,000
Change %
Price: $0.000000
Shares after: 210,000
Date: 14 Apr 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 210,000
Exercise price: $6.17

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.

Footnote F2

Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.

Footnote F4

The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock prices.